(Total Views: 848)
Posted On: 07/30/2020 8:48:05 PM
Post# of 153907
What type of narrative can we develop thus far about the efficacy/ safety of leronlimab?
Regarding the Mild to moderate covid 19 patient group -
Leronlimab is not only safer than placebo, but actually reduces SAE's by 64%. We are observing a strong resolution of symptoms in the treatment group versus the placebo group by day 3 (Primary endpoint hit) which is consistent with all of the data thus far from the eIND patients. Leronlimab also causes a strong reduction in the need for critical care intervention (NEWS2 secondary endpoint hit) versus placebo in days 3, 7 AND 14. Leronlimab also clearly reduces the need for oxygen support (Second secondary endpoint hit) AND mechanical intubation versus placebo group overall (third secondary endpoint hit).
In summary -
Leronlimab is beyond safe. It begins working in a clinically meaningful way within 3 days. It will prevent SAEs. It will reduce need for critical care intervention at 3 different time intervals. It will keep patients off oxygen and off mechanical ventilation.
More efficacy data inbound.
Regarding the Mild to moderate covid 19 patient group -
Leronlimab is not only safer than placebo, but actually reduces SAE's by 64%. We are observing a strong resolution of symptoms in the treatment group versus the placebo group by day 3 (Primary endpoint hit) which is consistent with all of the data thus far from the eIND patients. Leronlimab also causes a strong reduction in the need for critical care intervention (NEWS2 secondary endpoint hit) versus placebo in days 3, 7 AND 14. Leronlimab also clearly reduces the need for oxygen support (Second secondary endpoint hit) AND mechanical intubation versus placebo group overall (third secondary endpoint hit).
In summary -
Leronlimab is beyond safe. It begins working in a clinically meaningful way within 3 days. It will prevent SAEs. It will reduce need for critical care intervention at 3 different time intervals. It will keep patients off oxygen and off mechanical ventilation.
More efficacy data inbound.
(12)
(0)
